Literature DB >> 15739215

Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.

A G Renehan1, M P Saunders, P F Schofield, S T O'Dwyer.   

Abstract

BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
RESULTS: There were 99 local disease failures (39.0 per cent), all but five occurring within 3 years of initial treatment. Increasing age (P < 0.001, Cox model), total radiation dose (P = 0.004) and tumour stage (P = 0.010) were independent predictors of local failure. The overall 3- and 5-year survival rates after local disease failure were 46 and 29 per cent; the corresponding rates after salvage surgery (73 patients) were 55 and 40 per cent. A positive resection margin was the strongest negative predictor of survival after salvage surgery (P = 0.008, log rank test). Of 52 patients treated before the routine consideration of primary plastic reconstruction, delayed perineal wound healing occurred in 22 (42 per cent).
CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction. By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team. Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15739215     DOI: 10.1002/bjs.4908

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  19 in total

1.  Neoplasms of anal canal and perianal skin.

Authors:  Daniel Leonard; David Beddy; Eric J Dozois
Journal:  Clin Colon Rectal Surg       Date:  2011-03

2.  Epidermoid cancers of the anal canal: current treatment.

Authors:  Jennifer Blumetti; Amir L Bastawrous
Journal:  Clin Colon Rectal Surg       Date:  2009-05

3.  Abdominoperineal resection and perineal wound healing in recurrent, persistent, or primary anal carcinoma.

Authors:  J Hardt; S Mai; C Weiß; Peter Kienle; J Magdeburg
Journal:  Int J Colorectal Dis       Date:  2016-03-31       Impact factor: 2.571

Review 4.  Systemic Therapies for Advanced Squamous Cell Anal Cancer.

Authors:  Francesco Sclafani; Sheela Rao
Journal:  Curr Oncol Rep       Date:  2018-05-04       Impact factor: 5.075

5.  The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery.

Authors:  I Giani; M Mistrangelo; C Fucini
Journal:  Tech Coloproctol       Date:  2012-11-10       Impact factor: 3.781

6.  Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.

Authors:  Francesco Sclafani; Federica Morano; David Cunningham; Chiara Baratelli; Eleftheria Kalaitzaki; David Watkins; Naureen Starling; Ian Chau; Sheela Rao
Journal:  Oncologist       Date:  2017-02-16

7.  Epidermoid carcinoma of the anal canal.

Authors:  Bruce W Robb; Matthew G Mutch
Journal:  Clin Colon Rectal Surg       Date:  2006-05

Review 8.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Authors:  Rob Glynne-Jones; David Tan; Robert Hughes; Peter Hoskin
Journal:  Nat Rev Clin Oncol       Date:  2016-01-27       Impact factor: 66.675

9.  Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors.

Authors:  Espen Rusten; Bernt Louni Rekstad; Christine Undseth; Dagmar Klotz; Eivor Hernes; Marianne Grønlie Guren; Eirik Malinen
Journal:  Br J Radiol       Date:  2019-03-11       Impact factor: 3.039

10.  International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.

Authors:  Sheela Rao; Francesco Sclafani; Cathy Eng; Richard A Adams; Marianne G Guren; David Sebag-Montefiore; Al Benson; Annette Bryant; Clare Peckitt; Eva Segelov; Amitesh Roy; Matt T Seymour; Jack Welch; Mark P Saunders; Rebecca Muirhead; Peter O'Dwyer; John Bridgewater; Shree Bhide; Rob Glynne-Jones; Dirk Arnold; David Cunningham
Journal:  J Clin Oncol       Date:  2020-06-12       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.